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Abstract
In more than 30% of B-cell precursor acute lymphoblastic leukaemia (B-ALL), chromosome 21 sequence is overrepresented
through aneuploidy or structural rearrangements, exemplified by intrachromosomal amplification of chromosome 21 (iAMP21).
Although frequent, the mechanisms by which these abnormalities promote B-ALL remain obscure. Intriguingly, we found copy
number neutral loss of heterozygosity (CN-LOH) of 12q was recurrent in iAMP21-ALL, but never observed in B-ALL without
some form of chromosome 21 gain. As a consequence of CN-LOH 12q, mutations or deletions of the adaptor protein, SH2B3,
were converted to homozygosity. In patients without CN-LOH 12q, bi-allelic abnormalities of SH2B3 occurred, but only in
iAMP21-ALL, giving an overall incidence of 18% in this sub-type. Review of published data confirmed a tight association
between overrepresentation of chromosome 21 and both CN-LOH 12q and SH2B3 abnormalities in B-ALL. Despite relatively
small patient numbers, preliminary analysis linked 12q abnormalities to poor outcome in iAMP21-ALL (p= 0.03). Homology
modelling of a leukaemia-associated SH2 domain mutation and in vitro analysis of patient-derived xenograft cells implicated the
JAK/STAT pathway as one likely target for SH2B3 tumour suppressor activity in iAMP21-ALL.
Introduction
Intrachromosomal amplification of chromosome 21
(iAMP21-ALL) defines a distinct, high-risk sub-group
comprising 2% of precursor B-lineage acute lymphoblastic
leukaemia (B-ALL) [1, 2]. Originating through breakage-
fusion-bridge cycles and chromothripsis, rearrangements of
chromosome 21, giving rise to iAMP21, although chaotic,
result in common regions of genomic amplification and
increased gene expression [3, 4]. The precise mechanism by
which iAMP21 promotes leukaemia is currently unknown,
but is assumed to involve increased expression of genes or
functional non-coding sequences within the chromosome 21
amplified regions. Other structural amplifications of chro-
mosome 21 (OSA21), such as isochromosome 21, i(21q),
are rare but gains of one or more copies of whole chro-
mosome 21 (wc21) are extremely common. Notably chro-
mosome 21 is the only chromosome always overrepresented
in high hyperdiploid, hypodiploid and near-haploid ALL
[5, 6], which together account for about 30% of B-ALL.
Somatically acquired trisomy or tetrasomy 21 may also
be present as sole aneuploidies [7] and, individuals with
constitutional trisomy 21 (Down syndrome, DS) are at an
~20-fold increased risk of developing B-ALL [8, 9].
Deletions of RB1 and EBF1, mutations affecting the RAS
pathway, CRLF2 activating rearrangements, gain of the X
chromosome and partial deletion of chromosome 7 are all
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enriched in iAMP21-ALL [4, 10–12]. Suggesting a mechan-
istic link between iAMP21 and overrepresentation of whole
chromosome 21, some of these secondary abnormalities also
occur at high frequency in hyperdiploid or DS-ALL [13, 14].
Duplication of part of the maternal or paternal genome
with concurrent loss of equivalent sequence from the other
parental chromosome, known as copy number neutral loss
of heterozygosity (CN-LOH), can have pathological con-
sequences, through imbalance of expression of imprinted
loci or conversion to homozygosity of inherited or acquired
mutations and copy number abnormalities (CNA). In B-
ALL, only deletions of the CDKN2A/B genes have been
clearly linked to CN-LOH 9p [15–20], but other
regions were recurrent, suggesting that they harbour
imprinted or mutated genes or CNA that contribute to ALL.
Here, we investigated CN-LOH in B-ALL with whole or
partial gain of chromosome 21. We uncovered a highly
specific association between CN-LOH 12q and the presence
of iAMP21/OSA21, or less frequently gain of wc21. We
further identified SH2B3 abnormalities as a target of CN-
LOH 12q and found that, with rare exceptions, previously
published cases of B-ALL with SH2B3 abnormalities also
harboured whole or partial amplification of chromosome 21.
Preliminary analysis of outcome linked these 12q abnorm-
alities to an increased risk of relapse in iAMP21-ALL.
Materials and methods
Patient and PDX material
Bone marrow or peripheral blood diagnostic, matched remis-
sion and/or relapse samples were obtained from patients in the
United Kingdom, Germany or the USA. Ethical approval and
consent was obtained for all patients in accordance with the
declaration of Helsinki. Cytogenetic results were reviewed by
the Leukaemia Research Cytogenetics Group [21]. PDX were
generated from stored viable bone marrow cells from patients
78, 72, 62 and 69 as previously described [22]. Patient sam-
ples were obtained as DNA or viable cells from the reference
laboratories or the Bloodwise Childhood Leukaemia Cell
Bank, UK. DNA was extracted from viable patient cells or
from blasts isolated from PDX spleens and purified over
FICOL, using the DNeasy Extraction kit (Qiagen, Manchester,
UK). Study specific IDs and references, for patients with
whole or partial overrepresentation of chromosome 21, that
have been previously reported [4, 10, 11, 22, 23] are indicated
in supplementary table S1.
Definition of chromosome 21 CN status
The majority of cases of iAMP21-ALL had been
diagnosed on the basis of cytogenetic identification of an
abnormal chromosome 21 and ≥3 additional RUNX1 FISH
signals, with probes hybridising to the RUNX1
genomic region [24]. iAMP21 was confirmed in these
cases from the characteristic chromosome 21 SNP 6.0 array
profiles, as previously described [3]. In a minority of cases,
where suitable material for cytogenetic or FISH
analysis was unavailable or <3 extra copies of RUNX1 were
present but flanking regions were more highly
amplified, iAMP21 was identified by SNP 6.0 array CN
profile alone (supplementary figure 4). Constitutional or
somatically acquired aneuploidy 21 was identified by
cytogenetic analysis and confirmed by SNP array as
increased whole chromosome 21 CN. A minority of aneu-
ploidies were defined on the basis chromosome 21 CN
profile alone. Other cases, collectively referred to as other
structural amplifications of 21 (OSA21), included those
identified by cytogenetics as isochromosome 21q, i(21q), or
isodicentric 21, idic(21), and less clearly defined abnorm-
alities, which failed to meet our definitions of iAMP21 or
aneuploidy. The techniques used to define chromosome 21
CN abnormalities are shown in Supplementary Table 1b for
each case.
Techniques described in the supplementary
methods
Detailed methods for; SNP6.0 and methylation array ana-
lysis, Sequencing of SH2B3, homology modelling, western
blots, STAT and ERK activation assays and statistical
analysis are provided in the supplementary methods.
Results
The landscape of CN-LOH in B-ALL patients with
whole or partial gain of chromosome 21
From analysis of SNP6.0 arrays, we first determined the
frequency and genomic location of CN-LOH in B-ALL
patients with iAMP21-ALL (n= 49), OSA21-ALL (n= 11)
and two (n= 5) or one (n= 34) extra entire copy of chro-
mosome 21, either as a constitutional or acquired single
aneuploidy or within a hyperdiploid or hypodiploid kar-
yotype. Excluding two patients with multiple regions, that
we attributed to consanguinity [25], five cases showed
whole chromosome CN-LOH (wcCN-LOH), 27 involved
interstitial regions (iCN-LOH) and 19 were terminal (tCN-
LOH) (Fig. 1 and Supplementary Table 1a/b). In agreement
with previous reports [16, 26], tCN-LOH were of somatic
and iCN-LOH of germline origin as deduced from those
cases with available matched, non-leukaemic samples.
Notably, eight tCN-LOH involved the long arm of chro-
mosome 12 (12q), six occurring in iAMP21-ALL and two
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in OSA21-ALL (Fig. 2a). Other recurrent regions involved
the short arms of chromosomes 6 and 9 (6p, 9p) or whole
chromosome 9 (wc9).
tCN-LOH 12q is unique to a background of whole or
partial amplification of chromosome 21
We then screened 203 B-ALL patients with normal chro-
mosome 21 copy number (CN) and found tCN-LOH 9p in
10 cases but none involving 12q or 6p (Supplementary
Table 2). To validate findings within our own institution, we
investigated CN-LOH 12q and 6p among 974 patients from
a broad range of B-ALL subtypes from six published stu-
dies (Table 1) [6, 15–17, 19, 20]. In patients with disclosed
chromosome 21 CN status, 6p CN-LOH was associated
with both partially amplified (n= 3) and apparently normal
chromosomes 21 (n= 3). Among cases with CN-LOH 12q,
one was described as iAMP21-ALL [17] and two co-
occurred with amplifications of 21q to CN > 5 [15], thus
were likely iAMP21-ALL. The remaining case harboured
tetrasomy 21 [16]. So, taken together with our data, CN-
LOH 12q was exclusive to a background of whole or partial
chromosome 21 CN gain. The incidence, while only 0.9%
among B-ALL patients overall, was 13% among our cohort
of iAMP21/OSA21-ALL. The overall incidence of CN-
LOH 6p was 1.1% and, not exclusive to, but possibly
enriched in association with whole or partial gain of chro-
mosome 21, as it occurred at a rate of 3% among our cases
with and never without these abnormalities. A 70.3 Mb
common region of 12q tCN-LOH was defined from our
cases, with breakpoints clustered between the centromere
and chromosome band 12q14 (Fig. 2a and Supplementary
Table 1b).
CN-LOH 12q does not unmask an imprinted gene
To explore the possibility that CN-LOH caused unbalanced
expression of an imprinted locus on 12q, we compared
methylation array data from seven of the cases with CN-
LOH and an equal number of iAMP21-ALL patients
Fig. 1 The landscape of CN-
LOH in B-ALL with whole or
partial overrepresentation of
chromosome 21. Identification
(ID) numbers and chromosome
21 CNA are shown in the left
hand columns for patients
carrying regions of CN-LOH
identified by analysis of SNP 6.0
arrays. Chromosome numbers
are indicated in the top panel
and CN-LOH status for each
patient by box colour as shown
in the key. For patients with an
available remission sample, the
origin was defined as somatic
(not present in remission) or
germline (present in remission)
with iCN-LOH always identified
as germline and all but one tCN-
LOH defined as somatic.
Chromosomal position of CN-
LOH is indicated by; p
(segment/s of the short arm), q
(segment/s of the long arm) pq
(segments of both short and long
arms but not the whole
chromosome), wc (whole
chromosome). Multiple regions
of CN-LOH that were
predominantly interstitial, seen
in patients 41 and 93, are
indicative of consanguinity.
tCN-LOH 6p (n= 2), 9p (n= 4)
and 12q (n= 8) and wcCN-LOH
9 (n= 2) were recurrent
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without evidence of a 12q abnormality. Specific genes;
DCN, WIF1, FBRSL1 and E2F2, had been predicted to be
imprinted and fell within the 12q common region of CN-
LOH (www.geneimprint.com/Catalogue _of Parent of Ori-
gen Effects). However no evidence was found for differ-
ential methylation, between the two groups, of probes
associated with these genes (Supplementary Figure 1).
Furthermore analysis of the entire 12q common region of
CN-LOH revealed no significant blocks of differential
methylation between cases with and without CN-LOH.
Therefore we concluded that CN-LOH 12q was not driven
by loss of imprinting in these cases.
Fig. 2 Co-occurrence of 12q CN-LOH, amplification of chromosome
21 and deletion of SH2B3. a On the left SNP 6.0 genotype profiles
show the relative signal intensity of the B allele probes for chromo-
some 12. Normal genomic regions are characterized by three levels of
intensity corresponding to the AA, AB and BB genotypes and regions
of CN-LOH by loss of the AB genotype. Arrows mark the proximal
boundary of CN-LOH which were terminal in each case. To the right
are shown patient IDs and chromosome 21 log 2 CN profiles, black
lines mark the mean signal intensity for a CN of 2. All patients showed
evidence for structural amplification of chromosome 21, as indicated,
six abnormalities were defined as iAMP21. b Heat maps of CN for a
region of 12q showing clonal deletion in two patients with 12q CN-
LOH. Both deletions were bi-allelic with the smaller of the two con-
fined to exons of SH2B3 and ATXN2. c Suggesting they target a
common underlying genomic abnormality, allelotype and CN heat
maps for a presentation sample from patient 78 (P 78) were consistent
with the presence of competing sub-clones carrying 12q CN-LOH and
a mono-allelic deletion that included the SH2B3/ATXN2 region. In a
PDX derived from the same sample (PDX 78), CN-LOH was lost
while the deletion became clonal. To the right a detailed view of dot-
plots of SNP 6.0 CN within the deleted region, suggests the presence
of a somatically acquired bi-allelic micro-deletion centred on exon 2 of
SH2B3 in both patient and PDX samples but not the remission sample
(R 78). Black lines indicate a copy number of 2. Arrows indicate the
position of SH2B3 exon 2. d Sequence amplified from patient 78 using
SH2B3 intron 1 and 2 primers that defines breakpoints for a 17.4 Kb
deletion. e SNP6.0 CN heat maps of deletions that included the SH2B3
region found in three iAMP21 patients without CN-LOH 12q. In
patient 61 the deletion is mono-allelic while in patients 3 and 72 nested
deletions resulted in bi-allelic loss of SH2B3
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Deletions of the SH2B3 gene are coincident with CN-
LOH 12q
We next investigated regions of CN-LOH 12q for coin-
cident CNA and identified two with clonal deletions that
focused attention on a region containing SH2B3 and ATXN2
(Fig. 2b and Supplementary table 3). In a third patient, and
the patient-derived xenografts (PDX), sub-clones with 12q
deletion or CN-LOH fluctuated in level, suggesting that
competing sub-clones targeted a lesion on the second allele
through different mechanisms. Close examination of pre-
sentation and PDX array data revealed evidence for an
intragenic deletion of SH2B3 centred on exon 2, not present
in a remission sample (Fig. 2c). Loss of exon 2 was con-
firmed by PCR amplification of sequence from this sample,
but not a normal control, using SH2B3 intron 1 and 2 pri-
mers, which defined the breakpoints of a 17.4 Kb deletion
(Fig. 2d). Albeit at low frequencies, mutations and CNAs of
SH2B3 have previously been described in B-ALL [27–30],
so we further investigated this gene in iAMP21 and other
sub-types of ALL.
Deletions of SH2B3 in the absence of CN-LOH are
recurrent in iAMP21-ALL
We then analysed SNP6.0 arrays for 12q CN status in
patients from our cohort with or without whole or partial
chromosome 21 gain, without 12q CN-LOH. We identified
a clonal mono-allelic and two bi-allelic deletions affecting
SH2B3 in three cases of iAMP21-ALL (Fig. 2e and
Table S3). Deletion of SH2B3 was never seen outside
iAMP21-ALL. The combined incidence of 12q CN-LOH
and/or deletion of the region including SH2B3 was 9/49
(18%) in iAMP21-ALL, in marked contrast to non-
Table 1 The incidence and location by cytogenetic band of tCN-LOH 12q and 6q identified in this study or previously published cases of B-ALL
Study No. B-ALL
patients
Patient ID 12q CN-LOH 6p CN-LOH Chromosome 21 CN
status
Present study 302 5 12q13.1-12qtel iAMP21
12 12q14-12qtel OSA21
25 12q14-12qtel iAMP21
28 12q12-12qtel OSA21
44 12q11-12qtel iAMP21
45 12q13.1-12qtel iAMP21
78 12q13.1-12qtel iAMP21
88 12q14-12qtel iAMP21
71 6ptel-6p22.1 iAMP21
85 6ptel-6p21.2 iAMP21
Baughn 2015 [17] 65 Not reported 12q24.12-q24.32 iAMP21
Kawamata 2008 [15] 399 Not reported 12q? to 12qtel 21q CN > 5
Not reported 12q? to 12qtel 21q CN > 5
Not reported 6ptel-6p? Normal
Not reported 6ptel-6p? 21q CN > 5
Not reported 6pter-6p? 21 CN 3–4
Not reported 6pter-6p? 21 CN 3–4
Lundin 2016 [16] 181 28 6ptel-6p22.2 Normal
31 6ptel-6p22.1 Unknown
19 12q14.1-12qtel +21,+21
Mullighan 2007 [20] 192 TCF3-PBX1 #3 6ptel-6p22.1 Unknown
ETV6-RUNX1 #10 6ptel-6p21.1 Unknown
HD 47-50 #22 6ptel-6p22.1 Unknown
HD > 50 #34 6ptel-6p22.1 Unknown
Pseudodiploid #8 6p12.3-6p21.31 Unknown
Paulsson 2010 [6] 116 HD > 50 (All)
Ninomya 2012 [19] 21 AA214 6-p12.1-6pcen Normal
AA217 6p21.33-6p25.3 Normal
Position of CN-LOH and chromosome 21 CN reported by Kawamata [15] are estimated from Fig. 2a. HD (high hyperdiploid)
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iAMP21-ALL, where among 253 patients only two were
seen (0.8%) and both cases carried OSA21. The association
between amplification of chromosome 21 and CN-LOH/
deletion 12q was highly significant in our cohort (p ≤ 0.01).
To investigate a larger cohort with less bias towards chro-
mosome 21 abnormalities, we screened publicly available
SNP array data from 648 presentation B-ALL [28], identi-
fying just two with SH2B3 deletions, one with tetrasomy 21
and the other with no recorded evidence of a chromosome
21 CN abnormality (Supplementary Figure 2 and Supple-
mentary table 4). These data confirmed that, in the absence
of iAMP21/OSA21, deletion of the SH2B3 region is
extremely rare in B-ALL.
Mutations of SH2B3 are associated with CN-LOH and
heterozygous deletion of 12q in iAMP21-ALL
Although rare, mutations and deletions of SH2B3 have
previously been described in B-ALL [27–33], T-ALL [27,
34] and a range of myeloid neoplasms (reviewed in [35]). In
addition, polymorphisms of SH2B3 have been associated
with skewed haematological parameters and predisposition
to autoimmune disease or myeloid malignancy, the most
common of these is rs3184504, which results in a R262W
substitution that affects PH domain function [36, 37]. To
investigate involvement of polymorphisms or acquired
mutations, we carried out Illumina sequencing of coding
exons of SH2B3 in patients with CN-LOH and/or deletion of
12q (n= 9), as well as iAMP21-ALL patients without
identified 12q abnormalities (n= 6) (Table 2). In four cases
with bi-allelic deletion, as expected, no sequence abnorm-
alities were found, but frameshift mutations accompanied
12q CN-LOH without deletion (n= 2) or mono-allelic
deletion without 12q CN-LOH (n= 1). Of two remaining
patients with 12q CN-LOH, one carried an R392W poly-
morphism (rs770836648). This variant, which has a reported
frequency of 0.000016 in normal populations [38], was also
acquired in two patients with myeloproliferative disorders
[39]. In our case, R392W was evidently of somatic origin
because, although no remission sample was available, it was
identified in 49% of reads, while allelic bias due to CN-LOH
was 74%, as indicated by the read count for the rs3184504 C
allele. Based on the crystal structure of the mouse SH2B1
SH2 domain [40], we constructed a model of the equivalent
human SH2B3 sequence. This model strongly predicted that
substitution of the aromatic ring of tryptophan for the amino
Table 2 Position and
consequence of non-
synonymous sequence changes
identified in iAMP21-ALL
patients with and without 12q
CN-LOH and/or deletion of the
SH2B3 region
Patient
ID
12q CN-
LOH
SH2B3 CN Somatically acquired variants Germ line variants
Nucleotide sequence
change
Protein
sequence
change
Level p.R262W
AF C/T
Other
variant
(AF)
28 Yes 0 – 100/0%
25 Yes 2 c.1174C > T p.R392Wa 49% 74/26%
78 Yes 0b 93/7%
44 Yes 2 c.1566dupC p.E523Rfs 63% 100/0% p.G451S
(16%)
45 Yes 2 0/100%
88 Yes 2 c.1198_1199insCT p.E400Afs 69% 12/88%
12 Yes 0 – 100/0%
3 No 0 – 49/51%
61 No 1 c.760T > G p.C254G 52% 0/100%
61 No 1 c.763_773del p.SSIQ255-
258Gfs
50%
61 No 1 c.775_776delGA_insCG p.E259R 51%
19 No 2 – 100/0%
75 No 2 – 100/0%
77 No 2 – 100/0%
81 No 2 – 100/0%
84 No 2 – 0/100%
76 No 2 – 0/100%
areported as a rare germline variant (rs770836648)
bBi-allelic loss of start codon through exon 2 deletion. AF (Allelic Frequency) of R262W C / T alleles
indicates homozygosity when AF are 0/100 or 100/0. In heterozygous patients allelic bias, caused by CN-
LOH or deletion, is indicated by the ration of C and T alleles for the R262W variant
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group of the conserved 392 arginine residue would disrupt
normal interaction with the autophosphorylation site of
JAK2 (Fig. 3a–d) and likely equivalent sites on other
kinases.
Lastly, we postulated a predisposing role for R262W, as
re3184504 was homozygous for the T allele in patient 45,
the only case where 12q CN-LOH but no SH2B3 mutation
or deletion was identified. We also noted that rs3184504 was
never heterozygous in the six patients without 12q
abnormalities. However, homozygosity of R262W in patient
45 was unrelated to 12q CN-LOH, as further sequencing
demonstrated it was also homozygous in germline tissue and
sequencing of 16 additional iAMP21-ALL cases identified
the T/T, T/C and C/C genotypes in two, nine and five
patients, respectively. Thus it is it unlikely that rs3184504
contributes to iAMP21-ALL and we saw no evidence for
selection of other inherited SH2B3 variants.
Collectively, CN and sequencing data linked 12q CN-
LOH to bi-allelic loss of SH2B3 function, in all but one case
(Fig. 3e) and, although rare in B-ALL overall, we reasoned
that the incidence of SH2B3 abnormalities was highly ele-
vated in iAMP21-ALL. This finding prompted us to exam-
ine SH2B3 abnormalities previously reported in B-ALL in
the context of information relating to chromosome 21 CN
status (Table 3). Remarkably, we discovered that in the two
largest series described to date [28, 31], among 16 cases with
SH2B3 abnormalities, 12 carried previously unreported
iAMP21/OSA21 and four had gain of WC21 (personal
communications from M. Devidas on behalf of the Chil-
dren’s Oncology Group, USA). In other studies [27, 29, 30,
32, 41], we found only a single example where chromosome
21 CN status was defined and an SH2B3 abnormality was
not associated with iAMP21/OSA21/wc21 gain. This case
was also exceptional because an SH2B3 mutation was
inherited and unmasked by germline iCN-LOH [27].
STAT5 is activated by IL7 stimulation in iAMP21 cells
with SH2B3 deletion
In two studies, SH2B3 abnormalities co-occurred recur-
rently with potentially synergistic IL7R and/or FLT3 acti-
vating mutations [28, 31], prompting us to investigate IL7R/
JAK/STAT, FLT3/STAT and FLT3/RAS/RAF/ERK sig-
nalling pathways in iAMP21-ALL. PDX cells were used for
this purpose as diagnostic patient cells were not available.
We first demonstrated that SH2B3 protein was expressed in
cells derived from two patients without a 12q abnormality,
but not from cells derived from a patient carrying a bi-allelic
deletion of SH2B3. On stimulation with IL7, we observed a
clear dose dependent activation of STAT5, but not STAT1,
3, 4 or 6, in cells with SH2B3 inactivation. In contrast,
IL7 stimulation of cells without evidence of SH2B3 inac-
tivation showed no significant response to any STAT, while
FLT3 ligand failed to activate either STATs or ERK1/2 in
any of the cells tested (Fig. 4 and Supplementary Figure 3).
12q abnormalities may predict poor outcome in
iAMP21-ALL
We were able to investigate the outcome of 26 iAMP21-
ALL patients from this study who had been treated on
UKALL97/99 (n= 5) or UKALL2003 (n= 21) clinical
trials [1, 42]. After a median follow-up time of >5 years,
there was evidence of an association with outcome: 5/7
(71%) patients with CN-LOH or deletion of 12q had
relapsed and/or died compared with 4/19 (21%) patients
without 12q abnormality (p= 0.03). Importantly, iAMP21
patients treated on ALL97/99 had a significantly higher rate
of relapse compared with those treated on ALL2003 (70%
vs. 16% at 5 years) due to the intensification of treatment
received by these patients on UKALL2003 [1]. While
prognosis overall of iAMP21 patients treated on ALL97
was worse than in UKALL 2003, there remained a strong
association with 12q abnormality across both trials. This is
illustrated by the fact that none of the three ALL 97 treated
patients without 12q abnormality relapsed while 3/5 ALL
2003 patients with the abnormality relapsed/died.
Discussion
Supporting some of our key findings, two previous reports
noted an association between gross abnormalities of 12q
affecting the SH2B3 region and iAMP21-ALL [41, 43].
However, these studies were inconclusive as sequencing
was not performed to confirm the involvement of SH2B3.
Also the numbers of iAMP21-ALL cases analysed were
insufficient to accurately assess the overall incidence, pro-
portions affected by different types of lesions or influence
on outcome. We studied a larger cohort of patients, in which
we defined underlying SH2B3 sequence abnormalities and
performed preliminary analysis of outcome and also
extended our investigation to include published data. We
first established that in B-ALL, tCN-LOH 12q was exclu-
sive to B-ALL with iAMP21/OSA21 or, at low incidence,
with additional copies of wc21. Although existence of a
second target for CN-LOH 12q cannot be formally ruled
out, sequencing and copy number analysis identified bi-
allelic inactivation of SH2B3 as one consequence of these
abnormalities. As further support for SH2B3 as a relevant
target, we showed the same pattern of high incidence in
association with iAMP21-ALL and low incidence with
aneuploidy 21 when SH2B3 was inactivated in the absence
of CN-LOH 12q. Abnormality affecting SH2B3 without any
identifiable whole/partial chromosome 21 gain was extre-
mely rare, with only a single case reported within the
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literature and a second identified through analysis of
archival array data.
In our patients, all SH2B3 lesions were bi-allelic, with
CN-LOH being the dominant mechanism and deletion less
frequently involved in conversion to homozygosity. We
concluded that high copy number gain of specific sequences
on chromosome 21, as seen in iAMP21-ALL, confers
strong pressure for complete loss of SH2B3 function, while
Human SH2B3/ 359-462
Mouse Sh2b1/ 522-625
A
B C
R392W
D
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gain of one or two copies is associated with a similar though
weaker selective environment. The absence of reported
tCN-LOH 12q, in B-ALL without chromosome 21 gain,
may be explained by the extreme rarity of SH2B3 lesions
among these cases. In haematological malignancies other
than B-ALL, abnormalities of SH2B3 have not been asso-
ciated with 12q CN-LOH, suggesting less selective pressure
for homozygous inactivation. Consistent with lineage spe-
cific tumour suppressor thresholds, Tp53-/- SH2B3± mice
developed B-ALL in a manner that was strictly dependent
on loss of the wild type SH2B3 allele [44], while SH2B3±
mice developed a milder form of the myeloproliferative
disease seen in SH2B3 -/- mice [45]. We also note that in B-
ALL, SH2B3 abnormalities were mostly whole gene
deletions or truncating mutations, while in myeloid malig-
nancies, substitutions affecting the PH domain pre-
dominated (reviewed in [35]).
SH2B3 is one of a three member family of SH2B adaptor
proteins that share common motifs, including N-terminal
dimerization, pleckstrin homology (PH) and Src homology
2 (SH2) domains [46]. Of the three, SH2B3 has the most
prominent role in haematopoietic development, where it
negatively regulates various receptor and non-receptor
kinases, through direct interaction of the SH2 domain
with phosphorylated tyrosine (reviewed in [47]). Critically,
it functions in negative feedback loops controlling cell
growth, development and survival signals because activated
target kinases also induce SH2B3 expression and activation
through phosphorylation [44, 48, 49]. Our data clearly pose
the question of why SH2B3 loss of function should confer a
strong selective advantage to B-ALL, specifically when
certain chromosome 21 sequences are highly amplified
through complex rearrangements. The mechanism by which
iAMP21 promotes B-ALL is currently unknown and, in the
absence of representative cell lines or genetically engi-
neered animal models, challenging to investigate. Although
usually defined at the cytogenetic level by ≥3 additional
copies of RUNX1, there is little evidence that RUNX1
overexpression drives iAMP21-ALL. Despite higher
RUNX1 copy number in iAMP21-ALL, it was not shown to
be over-expressed relative to high hyperdiploid-ALL [23].
Furthermore B-ALL chromosome 21 copy number profiles
are occasionally iAMP21-like, but not highly amplified for
RUNX1 compared with flanking sequences (Supplementary
Figure 4). A second gene in the region, DYRK1A [3], is
more consistently amplified and has been implicated in
multiple signalling pathways contributing to cell growth
and survival and cancer (reviewed in [50]). In common with
B-ALL, the incidence of acute megakaryoblastic leukaemia
(AMKL) is highly elevated in individuals with DS and
Dyrk1A dosage increase was shown to co-operate with
Gata1 and Mpl mutations to promote AMKL [51]. Inter-
estingly, although we found no examples of SH2B3
abnormalities in DS-ALL, they were reported in DS-AMKL
but not non-DS-AMKL [52, 53]. Therefore also in this
highly specific haematological malignancy, SH2B3
abnormalities may be preferentially selected on a back-
ground of chromosome 21 gain, in this instance with
DYRK1A amplification demonstrated to be relevant.
Although it has not been shown that DYRK1A amplification
contributes to iAMP21-ALL, it does play a critical role in
the large to small pre-B cell transition stage, where it
induces quiescence through destabilisation of cyclin D3.
However, while pre-B cells in Dyrk1a deficient mice had
elevated levels of cyclin D3, they also displayed impaired
proliferation, suggesting involvement in other, cyclin D3
independent, aspects of B-cell differentiation [54]. In
Fig. 3 Impact of the R392W substitution and other SH2B3 abnorm-
alities. a 104 amino acid sequence comprising 92% of the SH2 domain
of human SH2B3 aligned to the mouse SH2B1 sequence. Black
arrows indicate three arginine residues required to coordinate pTyr813
of JAK2 within the mouse SH2B1 SH2 binding pocket. Red arrow
shows the position of the R392W arginine to tryptophan substitution
identified in patient 25. b Ribbon diagram based on the published co-
crystalized structure of the mouse SH2B1 SH2 domain and an eleven
residue phosphopeptide surrounding tyrosine pTyr813 within the
activation loop of JAK2 [40]. The structure has a canonical SH2
domain architecture with a central β-sheet (magenta) flanked by two α-
helices (cyan) that form two binding pockets for the JAK2 phospho-
peptide (shown as a stick representation with carbon atoms in green,
oxygen atoms in red, nitrogen atoms in dark blue and phosphate atoms
in orange). c A similar canonical SH2 domain structure is seen in a
homology model of 104 residues of the SH2 domain of human SH2B3
based on the mouse SH2B1 crystal structure. Overall sequence identity
between the two SH2 domains was 71%, with a structural homology of
1 Å RMSD when superposed. d Detailed view of superposed models
of the phosphotyrosine binding pocket of SH2 domains of mouse
SH2B1 (grey ribbons) and human SH2B3 (magenta ribbons) demon-
strating close structural homology for this region. The JAK2 phos-
phopeptide and three arginine residues (R534, R555 and R560) that
coordinate pTyr813 within the binding pocket through salt bridges
(broken black lines) are indicated by stick representations, with carbon
atoms of arginine in grey and other atoms coloured as in 3B. The
R392W substitution in human SH2B3 is also shown as a stick
representation with carbon atoms coloured in magenta. Tryptophan in
this position is unable to form salt bridges with pTyr813, the R392W
substitution therefore results in loss of two of four critical interactions
with phosphotyrosine and is predicted to destabilise binding of SH2B3
to activated JAK. e Summary of abnormalities of SH2B3 identified in
this study. At the top the SH2B3 linear protein structure is represented
with major functional domains marked; DIME (dimerization), PH
(Pleckstrin homology), SH2 (Src homology 2). For each patient,
genomic abnormalities of the SH2B3 coding region, as indicated in the
key, are aligned with the domain representation. Numbers on the left
are patient ids, genomic position of CN-LOH and deletion are indi-
cated on the right. The codon position and consequence of somatically
acquired mutations are as labelled, with arrows marking their positions
on the SH2B3 protein. Through combinations of mutation, deletion
and CN-LOH, SH2B3 abnormalities were all homozygous and pre-
dicted to result in absence of a coding transcript (patients 3, 12, 28, 72
and 78), production of truncated and likely unstable transcripts /
proteins (patients 44, 61 and 88) or production of a protein with
functionally impaired SH2 domain (patient 25)
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iAMP21-ALL, co-operating abnormalities, such as loss of
SH2B3 function, might therefore promote leukaemia by
fine-tuning a mixture of oncogenic and tumour suppressor
signals orchestrated by amplified DYRK1A. Like DYRK1A,
GSK-3β is a multifunctional serine/threonine kinase impli-
cated in diverse signalling pathways and both tumour pro-
moting and tumour suppressor roles (reviewed in [55]).
Interactions between GSK-3β and DYRK1A signalling
almost certainly occur in in B cells; for instance GSK-3β
also targets cyclin D for degradation [56] and is essential for
the phosphorylation and nuclear exclusion of NFAT tran-
scription factors, an event primed by DYRK1A and
implicated as an important consequence of increased wc21
CN in DS-AMKL [51]. GSK-3β activity is regulated by
posttranslational phosphorylation and in endothelial cells
phosphorylation mediated by integrin was shown to depend
on SH2B3 [57]. Loss of SH2B3 function could therefore
modulate signals orchestrated by increased dose of
DYRK1A through altered GSK-3β activity, although it
remains to be determined whether this contributes to B-
ALL.
Another likely arena for cooperation between abnorm-
alities of chromosomes 21 and 12 involves the JAK/STAT
pathway, because DYRK1A has been reported to
Table 3 Chromosome 21 CN
status in cases of B-ALL with
abnormalities of SH2B3 reported
in the literature
Study Diagnosis patient ID abnormality Sub-type chr 21 CN
status
Roberts 2014 [28] B-ALL SJBALL021786 p.L224fs Ph-like +21
B-ALL SJBALL021415 Deletion Ph-like +21
B-ALL SJBALL020013 Deletion Ph-like iAMP21a
B-ALL SJHYPO018 p.V402M Ph-like +21
B-ALL SJBALL020984 p.L347fs Ph-like iAMP21a
B-ALL SJBALL239 N/A Ph-like iAMP21a
B-ALL SJBALL021720 p.A98D Ph-like iAMP21a
B-ALL SJBALL021058 p.S245_E3splice Ph-like iAMP21a
B-ALL SJBALL021373 p.R398fs Ph-like iAMP21a
Perez-Garcia 2013 [27] B-ALL NA pD231fs NA Normal
B-ALL NA pQ427fs NA NA
Lindqvist 2016 [30] B-ALL (B) ALL-128 p.L188P/p.Q191fs/ p.
S192R/p.193_194del
Other NA
B-ALL (B) ALL-109 p.G312V t(12;21) NA
Olsson 2015 [29] B-ALL 2 Deletion Other NA
B-ALL 5 Deletion iAMP21 iAMP21
B-ALL 20 fsb HeH +21
B-ALL N/A p.S213R NA NA
B-ALL N/A p.E78K NA NA
B-ALL N/A p.R175W NA NA
B-ALL N/A p.R397G NA NA
Ivanov Ofverholm 2016
[41]
B-ALL KSALL12 Deletion iAMP21 iAMP21
B-ALL KSALL20 Deletion iAMP21 iAMP21
B-ALL KSALL44 Deletion iAMP21 iAMP21
Reshmi 2017 [31] B-ALL PAVJMN Missenseb Ph-like iAMP21a
B-ALL PAUZPC Deletion Ph-like iAMP21a
B-ALL PAVUJK Deletion Ph-like iAMP21a
B-ALL PAUXDJ fsb Ph-like iAMP21a
B-ALL PAWBPX Deletion Ph-like iAMP21a
B-ALL PAVGVK Deletion Ph-like iAMP21a
B-ALL PAVMFF Deletion Ph-like +21, +21,
+21a
Russell 2017 [32] B-ALL 11706 fsb iAMP21 iAMP21
aChromosome CN status not disclosed on publication, personal communication from M. Devidas on behalf
of the Childrens Oncology Group USA
bsequence change not presented
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phosphorylate STAT3 [58] and SH2B3 has been shown to
negatively regulate JAK signalling [27, 44]. The only non-
frameshift mutation identified among our cases was
demonstrated, by homology modelling, to result in loss of
interactions that repress activated JAK. Moreover, we found
that iAMP21-ALL PDX cells with SH2B3 bi-allelic dele-
tions were more sensitive to IL7 induced STAT5 activation
than those with wild type SH2B3. Evidence is also accu-
mulating that in B-ALL, loss of SH2B3 function cooperates
with abnormalities in addition to those of chromosome 21.
Further implicating the JAK/STAT pathway, IL7R
activating mutations were report in 8 of 16 cases with
SH2B3 abnormalities [28, 31]. However the emerging
picture is complex because other JAK-STAT pathway
activating abnormalities appear to correlate negatively with
SH2B3 inactivation. For example JAK mutations were
absent and only a single CRLF2 activating rearrangement
co-occurred with an SH2B3 abnormality [28]. Among our
iAMP21 patients tested for PAR1 deletions, that result in
the P2YR8-CRLF2 and consequent CRLF2 over-expression,
none were apparent in cases with (n= 7), but they
were seen in 5 out of 26 cases (19%) without 12q
abnormalities (data not shown). It may be that a background
chromosome 21 gain promotes selection for activation of
JAK/STAT, but not beyond a certain threshold. Cross talk
between other pathways influenced by the various JAK/
STAT activating rearrangements, may also favour
selection of certain combinations but not others. SH2B3 is
known to interact with other receptor and non-receptor
kinases, such as FLT3 and LCK, that play a role in early B-
cell development [49, 59]. We were unable to demonstrate
ERK or STAT activation in SH2B3 deleted PDX cells sti-
mulated with FLT3 ligand nevertheless abnormalities acti-
vating FLT3 appear to be co-selected with those
inactivating SH2B3 [28, 31] and a role in dysregulation of
the RAS/RAF/MEK/ERK pathway should not be dis-
counted. Although JAK-STAT and RAS pathway activation
clearly contributes to iAMP21-ALL [11], these pathways
are also commonly activated in patients without chromo-
some 21 abnormalities. The near-exclusive relationship we
observed may therefore be driven by other SH2B3 inter-
actions involving pathways dysregulated by high expression
of DYRK1A and/or other genes amplified through iAMP21-
ALL rearrangements. Notwithstanding these considerations,
CN-LOH/deletion 12q may function as useful markers for
cases that will potentially respond to JAK/STAT pathway
inhibitors, indeed blast counts were reduced in PDX from
one patient with IL7R activating mutation and SH2B3
deletion treated with ruxolitinib [33].
Importantly, we showed 12q abnormalities to be asso-
ciated with an increased rate of treatment failure in
iAMP21-ALL. Given the number of patients involved and
level of significance, this finding is preliminary, but if
confirmed in larger studies, may have important implica-
tions as iAMP21-ALL patients are classified as high risk [1]
and currently at risk of the adverse consequences of inten-
sive chemotherapy. Lastly further analysis of the tumour
suppressor role of SH2B3 in B-ALL may help to define
Fig. 4 IL7 stimulates activation of STAT5 in iAMP21-ALL cells with
SH2B3 deletion. a Immuno-blot with anti-SH2B3 confirmed loss of
expression in PDX of patient 72 that carry a bi-allelic deletion of
SH2B3. The full length protein was detected in patients 62 and 69
PDX that showed no evidence for SH2B3 CN or coding sequence
abnormalities. MWM (molecular weight marker) with 70 Kd band
shown. b Treatment of PDX cells carrying SH2B3 bi-allelic deletion
with IL7 resulted in a dose related increase in STAT5 phosphorylation
(four flow cytometric immunophenotyping experiments with cells
from patient 72) *(P < 0.01) **(P < 0.05). c Analysis of PDX cells
expressing wild-type SH2B3 failed to demonstrate any significant
increase in STAT5 phosphorylation with IL7 treatment (four flow
cytometric immunophenotyping experiments with cells from patient
62 [n= 2] and 69 [n= 2]). P values are for paired t-tests, error bars are
standard error of the mean.
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critical signalling events elicited by increased doses of
chromosome 21 gene expression in iAMP21-ALL, as well
as other important sub-types with gain of wc21.
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